Donald Trump urged to target ‘lazy patent expansion’ in US drug bill push

Unlock FREE White House Watch Newsletter

Washington, Trump’s second word for business and the world is your guide for him

Donald Trump, the CEO of the world’s largest generic drugmesers, has called on to deal with “lazy patent expansion” to cut the US drug bill, as the US President to reduce the price of drugs for Americans.

Switzerland’s Chief Executive Richard Sainner said he supported the purpose of the “most favorable country” policy in the administration – where it wants to cut the prescription Drug price At the lowest level provided by other rich countries – however, he said that more attention needs to be paid to the plight of generic drugs, which are 90 percent used in the United States.

The generic drugs produced after the expiry of the patent are usually about 80 percent cheaper than the branded versions. The United States pays less for generic drugs than in many European countries due to the concentration of buyers, leading to a situation where many drug manufacturers stop supplying drugs, creating deficit.

Sainner said that branded drugmeters – which are also known as promoters or inventors – they doubled the number of patents filed for their intellectual property in the past decade, causing the long and risky court fighting for generic manufacturers that delay their availability of cheap products.

“At this point, there are very low risk for promoters” that their products are “forever” – the practice of adjusting a little into a drug to protect new patents. “If you are an inventor you are rewarded to make it stronger and tightened and and and and and [patent] Offices are not rewarded for withdrawing patents. They get paid for filing. So again, you have a system that reward more patents. ”

Trump said last week that he had planned to reduce the price of “about 30 percent to 80 percent” about 80 percent. According to Rand Healthcare research, the United States paid about 3.2 times more for branded drugs than other developed countries in the United States.

Trump has signed an executive order that gives the drug manufacturers a target and cut the intermediaries, allowing patients to buy drugs directly. He also said that US trade representatives and trade departments should be investigated that only allow the market access to the market after a significant price discount.

The administration has not yet planned any major change in the generic market in the United States. However, the possibility of tariffs on pharmaceuticals, which is being investigated as part of the so -called section 232 investigation, is being investigated as a threat of importing national protection, the generic industry will hit the most because they have thin margins and are often dependent on production in India.

Sainner said that a generic drug makers should be reverted to a prize for the manufacturers that gave them a six -month exclusion after launching the first generic version of a drug, which helped compensate for the legal risk they were taking.

He said that branded drugkeepers created so -called allowed generic to capture this benefit and used “Patent Thickets” as a “extremely expensive and complex process” to “bring it to market.”

Sainner also criticized the concession arrangements that kept the total price high in the United States, because many intermediaries, known as Pharmacy Benefit Manager, were gaining from the exemption system. He said that the United States was “addicted to discounts”, whose price was “distorted impact” in terms of determining.

Many essential drugs such as antibiotics and anthhetics are generic. Sainar said that it was important to conversation about “sustainability of supply”. “You know, we sell an antibiotic for cheaper than the packet of M&MS,” he adds. “It’s offensive.”